Hepatic Antiviral Drugs Market

Hepatic Antiviral Drugs Market - An Overview

The global hepatic antiviral drugs market is expected to witness strong growth during the forecast period between 2021 and 2031.

Hepatic antiviral drugs are medicines which are extensively deployed in the treatment of different hepatic diseases such as Hepatitis A, Hepatitis B, and Hepatitis C.

Some of the hepatic antiviral drugs that have gained popularity include Adefovir, Entecavir, Lamivudine, and Tenofovir. These drugs are available in tablet, powdered, liquid, and solution forms.

Hepatic antiviral drugs have been made available in various online distribution channels such as ecommerce websites, which is expected to contribute significantly to global market growth, in future.

COVID-19 pandemic adversely affected the growth in the overall hepatic antiviral drugs market. With key resources such as doctors and nurses assigned to cure patients suffering from the virus at various healthcare facilities, it led to reduced labor force to treat patients suffering from different hepatic diseases.

This reduced the demand for hepatic antiviral drugs and impacted the growth in the overall hepatic antiviral drugs market, too.

Hepatic Antiviral Drugs Market - and Opportunities

Rising prevalence of hepatic diseases globally is the key growth driver for the hepatic antiviral drugs market.

Also, increasing expenditure on healthcare in leading economies worldwide is expected to fuel the growth in the global hepatic antiviral drugs market, in the coming years.

In addition to this, evolving dietary patterns and sedentary lifestyles among consumers could propel the global hepatic antiviral drugs market, in the years ahead.

Government initiatives and measures, spreading awareness about product features could bolster the overall hepatic antiviral drugs market, in future.

Other factors such as rising disposable income and growing awareness about treatment for hepatic diseases could play a key role in triggering the growth in the overall hepatic antiviral drugs market, in the years ahead.

Hospitals end-use segment is expected to contribute the most to the overall hepatic antiviral drugs market in future because of increasing product demand to cure patients suffering from hepatic diseases, at these facilities.

Hepatic Antiviral Drugs Market - Competitive Landscape

The global hepatic antiviral drugs market is highly competitive and comprises of several prominent market players, many of whom are expected to account for a large share in the overall market, in the coming years.

Prominent hepatic antiviral drugs market players could engage in growth strategies such as new product launches in a bid to gain a competitive edge over others.

Pfizer announced in December 2021 that it had received the approval for the emergency use of novel COVID-19 oral drug ‘Paxlovid Paxlovidtm’ for population sections above the age of 12.

Well-established hepatic antiviral drugs market players could collaborate with smaller players in a bid to expand their market presence and increase their revenue shares.

R&D undertakings to produce improved quality of drugs could be a key growth strategy prominent hepatic antiviral drugs market players, in the years ahead.

Some of the leading players in the global hepatic antiviral drugs market include Pfizer, GlaxoSmithKline PLC, Mylan N.V, AstraZeneca, and Zydus Cadila.

Hepatic Antiviral Drugs Market - Regional Assessment

North America is expected to be the dominant region in the global hepatic antiviral drugs market because of increasing prevalence of auto-immune disorders in countries such as US and Canada, contributing to market growth in the region.

Europe is expected to witness significant growth in the hepatic antiviral drugs market because of rising focus on developing novel technologies in countries such as Italy and Germany.

Asia Pacific is anticipated to witness strong growth in the overall market in future owing to rising population in countries such as India and China and growing prevalence of hepatic disorders in countries belonging to the region.

The rest of the world is expected to witness moderate growth in the global hepatic antiviral drugs market, in future.